Methods of diagnostic of liver fibrosis
AssigneeGenfit
InventorsSUNEIL HOSMANE, JÉRÉMY MAGNANENSI, YACINE HAJJI
Life of this patent
Estimating the term…
Abstract
The invention relates to a method for the identification of NAFLD patients likely to develop advanced liver fibrosis within 52 weeks.
Claims7
1-6. (canceled)
A method for the identification of a subject as having Non-Alcoholic Fatty Liver Disease (NAFLD) with high likelihood of progression to advanced liver fibrosis within the course of 52 weeks, wherein said method comprises the measure of the level of hsa-miR34a, alpha 2 macroglobulin (A2M), YKL40 and glycated hemoglobin (HbA1c) in a blood-derived sample of said subject, the levels measured being used in a logistic function to calculate a score S, wherein the score S is calculated according to the following logistic function:
- S
- ∼
- e
- Y
- 1
- +
- e
- Y
- wherein:
- Y=k+a*A+b*B+c*C+d*D
- wherein the method is derived from the bootstrap model, and wherein:
- S is the score;
- A is the serum level of hsa-miR-34a in Cq;
- B is the serum level of alpha 2 macroglobulin in g/L;
- C is the serum level of YKL-40 in pg/ml;
- D is the level of HbA1c in percent;
- K is the constant of the logistic function;
- a is a coefficient associated to the serum level of hsa-miR-34a;
- b is a coefficient associated to the serum level of alpha 2 macroglobulin;
- c is a coefficient associated to the serum level of YKL-40;
- d is a coefficient associated to the level of HbA1c;
- wherein:
- k is a number comprised between 9.51 and 34.37;
- a is a number comprised between −1.17 and −0.47;
- b is a number comprised between 0.02 and 0.84;
- c is a number comprised between 6.10E-06 and 2.09E-05;
- and
- d is a number comprised between 0.07 and 0.89;
- wherein the score S higher or equal to a cut off value, which is 0.63, is indicative of a high likelihood of progressing to advanced fibrosis within the course of 52 weeks.
Dependencies are inferred from the claim text.